Building Bridges

OHSU is reinventing technology transfer. Over the years the office has evolved from “Tech Transfer 1.0” to “Tech Transfer 3.0.” We’ve built out in-house patent counsel, added business development and technology ventures programs and engaged in economic development and public policy initiatives that enhance the economic vitality of our institution and our region.

2011 marked a year of achievement for Technology Transfer and Business Development. Highlights include the expansion of the team from 14 to 23 staffers who will help to capture and disseminate commercial opportunities. The year was capped by the completion of a record number of industry-sponsored research agreements (118) providing more than $12 million in awards for scientists. In addition, the office processed a record number of material transfer and nondisclosure agreements, finalizing nearly 750 total agreements during the year, an average of approximately three each business day.

With more in store for 2012, OHSU is committed to serving our faculty, our patients and the business community. Throughout these pages, you will find highlights of our activities along with a glimpse of the future as we work to build bridges that move research discoveries from concept to reality.

Sincerely,

J. Timothy Stout, M.D., Ph.D., M.B.A.
Vice President

Contents

2 Building Bridges
   A Message from the Vice President

3 2011 at a Glance
   Economic Impact

4 Solutions for Drug Discovery - Yecuris, Inc.
   Intellectual Property Management

5 Partnerships that Drive Innovation - The OHSU Personalized Cancer Medicine Registry
   Business Development

6 Impacting Global Health - Drs. David and Deborah Lewinsohn
   Technology Transfer

7 Changing the Standard for Cancer Detection - OHSU’s Advanced Imaging Research Center
   Technology Development

8 Honoring Innovation & Entrepreneurship at OHSU
   The 2011 Technology Innovation Awards

9 Technology Transfer and Business Development Staff

11 Metrics and Statistics: Fiscal Year

13 The OHSU Innovation System

On the cover: OHSU’s Aerial Tram
Photo courtesy of Ron Cooper
Discoveries
128 Invention Disclosures from OHSU Faculty

Patents
64 U.S. Patent Applications Filed
17 U.S. Patents Issued

Licensing
50 Commercialization Agreements Signed

Industry Collaborations
90 Industry Collaboration Agreements Signed

Technology Ventures
4 Startup Companies formed based on OHSU Research
3 Emerging Startups Supported (Springboard Program)

Economic Impact

OHSU Startup Companies
10 Year History

2002
Oxiquant
Znomics
Proteogenix

2003
Receptor Biologix
Orexigen
Vox Technologies
Verbeam
Attain Technologies
Thetus

2004
Columbia Biotechnologies
Advanced PsychSystems
Najit Technologies
Artielle ImmunoTherapeutics
BioSpeech
Revitus
AMES Technologies

2005
Restoration Genetics
Thiakis
The DNA Repair Co.
Recovexx
Northwest Education Training & Assessment

2006
Acute Innovations
SimHealth
NeuroProtect

2007
MolecularMD
I D Biopharma
Yecuris
Cylerus
Portland Bioscience

2008
Transmed Oncology
Cascade Lifesciences
Genefac
Flash Sensor Tech

2009
APDM
DeltaPoint
Receptor Therapeutics

2010
Aronora
Gamma Therapeutics
Odyssey Science Innovations

2011
TomegaVax
ViTi
UbiVac CMV
Technology Transfer and Business Development is responsible for assessing the commercial potential of research; marketing technologies to industry; and negotiating and managing commercialization agreements.

Other activities related to intellectual property include compliance and reporting to federal and non-federal sponsors; compliance with the Bayh-Dole Act; providing reports of the inventions to the sponsor; and distributing income received from licensing activities according to institutional and federal guidelines.

The office also accepts intellectual property transferred to OHSU from other institutions; provides reports to assist in identifying and managing conflict of interest issues; and reviews, interprets and disseminates federal and institutional intellectual property and technology transfer policies.

Yecuris was formed in April of 2007 to commercialize a transgenic mouse technology developed in the lab of Markus Grompe, M.D., Professor of Pediatrics and Molecular and Medical Genetics and Director of the Papé Family Pediatric Research Institute at OHSU.

Originally developed to explore pathways for hereditary type I tyrosinemia, an often fatal pediatric disease, the FRG mice have more recently been shown to be useful in a variety of drug discovery development techniques, including hepatocyte expansion, drug metabolism, and toxicology applications. One crucial area Dr. Grompe and his colleagues at the Oregon Stem Cell Center have been exploring is the use of the FRG mouse and associated methods in development of treatments for chronic and acute liver diseases, which afflict roughly 25 million individuals in the U.S. alone. OHSU has filed for patent protection on the technology, which is exclusively licensed to Yecuris. Additionally, the university, in conjunction with the company, has finalized over 60 transfers of the FRG mouse model to academic institutions throughout the world.

Prior to the launch of Yecuris, the lack of robust primary hepatic materials and models was an impediment to basic scientific research, timely delivery of drug candidates and cures, and the development of novel treatments for chronic and acute liver disease. The introduction of the Yeuris FRG mouse™ represents a significant advancement in the ability to provide researchers and clinicians with a dependable supply of these precious materials.

Yecuris was formed in April of 2007 to commercialize a transgenic mouse technology developed in the lab of Markus Grompe, M.D., Professor of Pediatrics and Molecular and Medical Genetics and Director of the Papé Family Pediatric Research Institute at OHSU.

Originally developed to explore pathways for hereditary type I tyrosinemia, an often fatal pediatric disease, the FRG mice have more recently been shown to be useful in a variety of drug discovery development techniques, including hepatocyte expansion, drug metabolism, and toxicology applications. One crucial area Dr. Grompe and his colleagues at the Oregon Stem Cell Center have been exploring is the use of the FRG mouse and associated methods in development of treatments for chronic and acute liver diseases, which afflict roughly 25 million individuals in the U.S. alone. OHSU has filed for patent protection on the technology, which is exclusively licensed to Yecuris. Additionally, the university, in conjunction with the company, has finalized over 60 transfers of the FRG mouse model to academic institutions throughout the world.

Prior to the launch of Yecuris, the lack of robust primary hepatic materials and models was an impediment to basic scientific research, timely delivery of drug candidates and cures, and the development of novel treatments for chronic and acute liver disease. The introduction of the Yeuris FRG mouse™ represents a significant advancement in the ability to provide researchers and clinicians with a dependable supply of these precious materials.
Over the past century, medicine has focused on the development of broad-spectrum drugs to treat or cure disease. This has been particularly true in the field of cancer, which relies on chemotherapeutic strategies that are known to kill the majority of tumors in a certain class.

These drugs kill both healthy and diseased cells and are not tailored to the specific profile of an individual's cancer. Enter personalized medicine, a medical model that focuses on the individual, using genetic or other information to optimize care.

OHSU’s Knight Cancer Institute is a pioneer in personalized cancer medicine and research. The Knight's director, Brian Druker, M.D., developed one of the first molecularly targeted drugs that could destroy the cells that enable cancer to grow without harming healthy ones. This breakthrough ushered in a new era of personalized cancer therapies.

Christopher Corless, M.D., Ph.D., Director of the Knight Diagnostic Labs at OHSU, is a tireless advocate for personalized medicine, both as co-discoverer of two novel cancer biomarkers and as the creator of numerous new molecular diagnostic assays.

He launched, and now manages, the Personalized Cancer Medicine Registry (PCMR), a novel initiative developed in collaboration with the pharmaceutical industry that uses state-of-the art genotyping technology to analyze the molecular makeup of a patient's tumor. The registry includes molecular, clinicopathologic, and staging information which is stored in a unique database that can be readily searched as trials of new targeted therapies emerge.

In addition to its clinical value, the PCMR is a powerful research tool that allows both academic and industry researchers to access tumor specimens and associated data. Using this tool, OHSU is an active collaborator with industry on projects which seek to identify new cancer biomarkers, assist with drug design and development, and create cutting-edge diagnostic assays.

OHSU is committed to a culture where partnerships flourish. The goals are simple - support strategic partnerships, remove barriers, and provide world-class resources. Technology Transfer and Business Development works to forge relationships with industry, the investment community, academia and government. With more than 1,100 principal investigators and more than 3,000 research projects, OHSU is a catalyst for bioscience and technology development.

The university has developed a strong infrastructure for commercialization and collaboration. The Research Consortium Program has identified and connected internal expertise in the areas of aging, autism, diabetes, pain, and rare diseases to provide cooperative resources for potential business partners. In turn, industry-academic collaborations have continued to grow and diversify, connecting researchers to alternative outlets for crucial project funding.
The Centers for Disease Control and Prevention estimates that one third of the world’s population is infected with tuberculosis (TB), with another 9 million individuals becoming sick with the disease each year.

While many researchers across the world are focused on better treatment, the need for prevention, particularly against the multi-drug resistant strains of the bacteria, is at an all time high.

That’s where Drs. David and Deborah Lewinsohn step in. They believe the best method for preventing the disease is a better vaccine. “If we really understood how the human-immune response contained tuberculosis, then that would be our model for a better vaccine” says David Lewinsohn, M.D., Ph.D., Associate Professor in Pulmonary and Critical Care Medicine at the Portland VA Medical Center and Immunology, and Associate Scientist at OHSU’s Vaccine and Gene Therapy Institute. Alongside his research partner and wife, Deborah, a pediatric infectious disease specialist and immunologist, they have over 20 years of research experience to drive their efforts.

They understand that collaboration is key to turning their vaccine development into reality. The Lewinsohns have identified dozens of antigens that show significant promise for early diagnosis and for the development of a human vaccine against TB.

In 2010, they formed ViTi, an OHSU startup company, to develop TB diagnostics for adults and young children. The company’s core technologies include a series of novel TB antigens and T cell clones as well as unique expertise in T cell expansion that will contribute to the development of TB diagnostics. They recently received Small Business Innovation Research (SBIR) funding to further develop the company’s diagnostic products.

Discoveries from OHSU laboratories expand the economy and improve overall health and quality of life. With schools in medicine, dentistry and nursing, the university generates discoveries in areas ranging from pharmaceuticals and medical devices to software and environmental health.

The goal of research commercialization is to bridge the gap between promising research and public benefit. The Technology Transfer and Business Development office licenses OHSU’s intellectual property; links businesses with OHSU technologies and expertise; negotiates industry collaborations; and launches companies based on OHSU research.
OHSU is at the forefront of medical imaging in the twenty-first century. The Advanced Imaging Research Center (AIRC) at OHSU is a world-class resource in medical diagnosis and scientific discovery, with cutting-edge research in imaging science.

The centerpiece of the AIRC is a collection of high resolution instruments, including a 12Tesla (T) system, capable of unprecedented resolution. The 12T MRI instrument has a magnetic field 120,000 times stronger than that of the Earth. OHSU is one of only a few research institutions in the world with a 12T system.

Xin Li, Ph.D., and his colleagues at the AIRC are investigating the dynamic contrast-enhanced (DCE) MRI image analysis technique to improve cancer diagnostic accuracy. Their research shows that use of the novel Shutter-Speed Model DCE MRI technique will improve breast cancer diagnostic accuracy and reduce unnecessary biopsy procedures on women with benign lesions. By adjusting the mathematics of the computer program analyzing the signals, the researchers can account for the movement of water molecules in and out of cellular compartments in diseased and healthy tissue.

In 2009, this breakthrough was selected for OHSU’s BioScience Innovation Program, which provides funding for emerging technologies at the university.

AIRC researchers are bringing the power of imaging science to bear on numerous multidisciplinary studies across OHSU, seeking new treatments and cures for conditions such as multiple sclerosis, cancer, stroke and chemical dependency.

The Technology Transfer and Business Development office at OHSU is a leader in technology transfer, creating new partnerships and business opportunities that support the research community and share the benefits of university discoveries with the public through the commercial marketplace.

However, no matter how promising a discovery may be, it faces challenges in bridging the gap between laboratory and commercial opportunity. Many of the risks associated with a new discovery can deter further research and/or financial investment. Our office works to close that gap, by expanding licensing opportunities, developing research and business collaborations and supporting startup companies.

OHSU’s Bioscience Innovation Program (BSIP) has created a resource for philanthropic support of promising research discoveries. Since 2004, the BSIP’s parent program, the Innovation & Seed Fund, has awarded $1.45m in funding to 16 technologies and 11 OHSU research-based startup companies.
Over 80 OHSU investigators were honored for their contribution to innovation and entrepreneurship during the 2011 Technology Innovation Awards. Keynote speaker Dr. Albert Starr, who pioneered the world’s first successful heart valve replacement, addressed the audience with his insight into over 40 years of medical innovation. Researchers received awards for technologies licensed, patents issued, startups formed based on technologies, and the top ten industry collaborations during the fiscal year.

### U.S. Patents Issued to OHSU Inventors in 2011

<table>
<thead>
<tr>
<th>U.S. Patent No.</th>
<th>Title</th>
<th>OHSU Inventor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7,968,682</td>
<td>Degradation Resistant Fibrinogen Sealants</td>
<td>David Farrell, Ph.D.</td>
</tr>
<tr>
<td>7,943,296</td>
<td>Methods of Screening using a Natriuretic Peptide Receptor</td>
<td>G. Michael Silberbach, M.D. Charles Roberts, Jr., Ph.D.</td>
</tr>
<tr>
<td>7,939,080</td>
<td>HER-2 Binding Antagonists</td>
<td>John Adelman, Ph.D.</td>
</tr>
<tr>
<td>7,914,567</td>
<td>Stent Tissue Graft Prosthesis</td>
<td>Dusan Pavcnik, M.D., Ph.D.</td>
</tr>
<tr>
<td>7,875,710</td>
<td>Nucleic Acids Encoding Platelet Derived Growth Factor Receptor Alpha (PDGFRA) Activating Mutations</td>
<td>Christopher Corless, M.D., Ph.D. Michael Heinrich, M.D.</td>
</tr>
<tr>
<td>7,871,430</td>
<td>Medical Device Delivery System</td>
<td>Dusan Pavcnik, M.D., Ph.D.</td>
</tr>
<tr>
<td>7,867,140</td>
<td>Device for Conditioning Balance and Motor Co-ordination</td>
<td>Fay Horak, Ph.D.</td>
</tr>
<tr>
<td>7,842,470</td>
<td>Method for Pharmacoperones Correction of GNRHR Mutant Protein Misfolding</td>
<td>P. Michael Conn, Ph.D.</td>
</tr>
<tr>
<td>7,842,299</td>
<td>Method for Producing an Immune Response to Tuberculosis</td>
<td>David Lewinsohn, M.D., Ph.D. Deborah Lewinsohn, Ph.D.</td>
</tr>
<tr>
<td>7,829,578</td>
<td>Aromatic Ketones and Uses Thereof</td>
<td>Michael Riscoe, Ph.D., Jane Kelly, Ph.D. Rolf Winter, Ph.D., David Hinrichs, Ph.D. Martin Smilkstein, M.D.</td>
</tr>
<tr>
<td>7,814,590</td>
<td>Accessory Panel for Diagnostic Platform, Patient Bed and other Support Surfaces</td>
<td>Susan Powell, R.N., Susan Duncan, R.N. Karen Ellmers, R.N., M.S.</td>
</tr>
</tbody>
</table>

### Top Sponsored Research Awardees

- Ov Slayden, Ph.D.
- Kevin Grove, Ph.D.
- Christopher Corless, M.D., Ph.D.
- Steven Jacques, Ph.D.
- Richard Stouffer, Ph.D.
- Richard Weleber, M.D.
- Tamara Hayes, Ph.D.
- Steven Kazmierczak, Ph.D.
- Eliot Spindel, M.D., Ph.D.
- David Huang, M.D., Ph.D.
- Sanjiv Kaul, M.D.
J. Timothy Stout, M.D., Ph.D., M.B.A.
Vice President
As the Vice President of TTBD, Tim’s role involves exploring prospective industry partnerships, startup and technology investment opportunities and leveraging OHSU’s discoveries. At OHSU’s Casey Eye Institute, he specializes in pediatric vitreoretinal diseases and surgery.
stoutt@ohsu.edu

Technology Development Managers

Michele E. Gunness, Ph.D.
Senior Technology Development Manager
Michele received a Ph.D. from the University of Connecticut. Following faculty positions at the UConn Health Center, OHSU and the Portland VA Medical Center, she embarked upon a career in technology transfer. She is active in the Licensing Executives Society as the past local chapter chair.
gunnessm@ohsu.edu

Andrew R.O. Watson, Ph.D.
Senior Technology Development Manager
Andrew previously served as a Technology Development Officer at The Scripps Research Institute and in tech transfer roles with Health Research Inc. and the Research Foundation for Mental Hygiene, Inc., both in New York. Andrew is a Certified Licensing Professional.
watsonan@ohsu.edu

Arvin Paranje, J.D., M.S.
Technology Development Manager
Arvin earned a law degree from Washington University in St. Louis and a M.S. in biotechnology from Johns Hopkins University. He possesses four years of experience as an electronics and high technology sector consultant for Fortune 500 companies. Arvin is a registered Patent Agent with the USPTO.
paranjpe@ohsu.edu

Technology Ventures & Marketing

Kristin Rencher, M.B.A.
Director, Technology Ventures & Marketing
Kristin has over 20 years of business and leadership experience in the life science, nonprofit and finance industries. At OHSU she manages a portfolio of programs which includes the Innovation and Seed Fund. She has served as VP for Communications for the Association of University Technology Managers.
rencherk@ohsu.edu

Kristen A. Andon, M.S.
Technology Marketing Manager
After a career as a validation engineer at Baxter Healthcare Corporation, Kristen received her M.S. in Technical & Scientific Communication from James Madison University. In addition to her role in TTBD, she is a freelance technical writer.
dincherk@ohsu.edu

Technology Transfer and Business Development Staff

Arundeep S. Pradhan, M.S.
Associate Vice President
Arundeep has a B.Pharm and M.S. in Pharmacy Administration. In addition to his role in TTBD, he was also the President of the Association of University Technology Managers (AUTM) in 2009 and currently serves as the President of the AUTM Foundation.
pradhana@ohsu.edu

Business Development

Abhijit Banerjee, Ph.D., M.B.A.
Director, Business Development
Jit holds a Ph.D. in Biochemistry from the Indian Institute of Chemical Biology. He is a recipient of Joseph Shankman Award from the National Kidney Foundation. He received his M.B.A. from Suffolk University. Prior to joining OHSU, Jit worked in the technology transfer office at Cornell University, at Deloitte Consulting, and in Pfizer’s Strategic Alliance group.
banerjea@ohsu.edu

Brittany Sale, M.S.
Business Development Coordinator
Brittany joined the TTBD team in 2011 after having completed a consulting position with the OHSU Research Human Resources Department. She earned an M.S. in Applied Social Psychology/Industrial-Organizational Psychology from Portland State University, during her PhD candidacy.
saleb@ohsu.edu

Robert Copenhaver, M.S., M.B.A.
Technology Development Manager
Rob has prior work experience in technology transfer, industry drug development, and as a business development consultant for a pharmaceutical-industry focused consulting firm. Rob has completed his M.S. at the University of Texas Health Science Center at Houston and earned an M.B.A. with honors from the University of Houston.
copenhar@ohsu.edu

Travis G. Cook, M.S., M.B.A.
Technology Development Manager
Travis has 7+ years of industry experience in small molecule, natural product, peptidomimetic, and mixture-based drug design. He received a M.S. in chemistry from UC San Diego, and a M.B.A. from Willamette University. He is a co-inventor on six patent applications and is co-author of several peer reviewed publications and a case study in the textbook, Building a Case for Biotechnology.
cooktr@ohsu.edu
Intellectual Property Management

Christopher L. Andon, M.S.
Patent Associate
Prior to joining OHSU, Chris worked as a patent agent for 5+ years at Portland area law firms focusing on biotech, medical device, and software/informatics patent prosecution. He holds a M.S. in Biomedical Informatics from OHSU and a B.S. in Biology from UC San Diego.
andonc@ohsu.edu

Technology Development Coordinators

Ruth Epling
Technology Development Coordinator
After six years of field research as a biologist with the Forest Service Pacific Northwest Inventory and Analysis group, Ruth joined OHSU as a Licensing Assistant in 2008. She was the 2010 recipient of the Howard Bremer Scholarship, awarded to rising talents in the technology transfer profession.
eplingr@ohsu.edu

Sangeeta Rojanala, Ph.D.
Technology Development Coordinator
Sangeeta earned a Ph.D. in Molecular and Cellular Biology, with a minor in cancer biology, from The University of Arizona. She has over 10 years of experience in the biotechnology industry and has authored and co-authored several peer reviewed publications.
rojanala@ohsu.edu

Trina Voss
Technology Development Coordinator
Trina received B.S. degrees in Zoology and Biology from Humboldt State University, completed graduate coursework in Marine Science at Moss Landing Marine Labs, and received an A.A. in Arabic Language from the Defense Language Institute. Prior to OHSU, Trina worked at the technology transfer office at the University of Southern California.
vosst@ohsu.edu

Finance & Administration

Simone Waddell
Finance Administrator
Simone brings over 10 years of finance/accounting experience to the TTBD team. Her work spans industries from semi-conductor manufacturing to film and television production. Simone received a B.A. in Linguistics with honors from the University of Rochester and is currently pursuing an M.B.A. with Portland State University.
waddells@ohsu.edu

Elaine Soljaga
Executive Assistant to J. Timothy Stout
soljagae@ohsu.edu

Jeffrey Jackson, M.S., J.D.
Patent Associate
After a 14-year career in biotechnology research, Jeff graduated from the Sandra Day O’Connor College of Law at Arizona State University. Prior to joining OHSU, he was the Intellectual Property Manager at the Translational Genomics Research Institute in Phoenix. Jeff holds an M.S. in Immunology from the University of Washington and a B.S. in Biological Sciences from Stanford.
jacksje@ohsu.edu

H. Tommy Pham, M.B.A.
Technology Development Coordinator
Tommy received his B.S. in Biology (minor in Chemistry) and M.B.A. in Technology Entrepreneurship from University of Portland. He is a recipient of the distinguished Horatio Alger Scholarship. Prior to joining OHSU, he was involved with the Portland State Business Accelerator and Keiretsu Forum as a business intern. Tommy currently serves as a member of the Oregon Bioscience Association Program Committee.
phamto@ohsu.edu

Christopher Stoner, Ph.D.
Technology Development Coordinator
Chris earned a Ph.D. degree in Biochemistry and Biophysics from Oregon State University, with a focus on oxidation-reduction based intracellular messaging systems. He is a registered patent agent with the USPTO and is currently attending Lewis & Clark Law School.
stonerc@ohsu.edu

Nicole D.W. Garrison
Executive Assistant to Arundeep S. Pradhan
Nicole Garrison received her bachelor’s degree from Lewis & Clark College and is currently a student in the Oregon Health & Science University/Portland State University Joint M.B.A. in Healthcare Management program.
garrisni@ohsu.edu

James R. LeFever
Office Specialist
James received his B.A. in social science from Marylhurst University. In addition to his duties as an Office Specialist, he runs his own small business teaching Taijiquan.
lefever@ohsu.edu
2011 Metrics and Statistics

Invention Disclosures, US Patents Filed and Issued

Invention Disclosures include those from the Schools of Medicine, Dentistry, and Nursing.

Industry Sponsored Research Collaborations
Non-Disclosure and License Agreements

Distributions (dollar amounts distributed to units)

<table>
<thead>
<tr>
<th>Unit</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>School of Medicine</td>
<td>257,471</td>
<td>1,717,396</td>
<td>722,165</td>
<td>359,290</td>
<td>258,793</td>
<td>3,315,116</td>
</tr>
<tr>
<td>School of Dentistry</td>
<td>910</td>
<td>277</td>
<td>--</td>
<td>733</td>
<td>172</td>
<td>2,093</td>
</tr>
<tr>
<td>School of Nursing</td>
<td>--</td>
<td>450</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>450</td>
</tr>
<tr>
<td>Research Development</td>
<td>116,336</td>
<td>58,996</td>
<td>37,702</td>
<td>90,352</td>
<td>140,760</td>
<td>444,146</td>
</tr>
<tr>
<td>Adminstration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1,234</td>
<td>--</td>
<td>--</td>
<td>240</td>
<td>--</td>
<td>1,473</td>
</tr>
<tr>
<td>Totals</td>
<td>375,951</td>
<td>1,777,119</td>
<td>759,867</td>
<td>450,615</td>
<td>399,726</td>
<td>3,763,278</td>
</tr>
</tbody>
</table>
The OHSU Effect

OHSU research has led to the creation of 43 spin-off companies since 2000. Of these, the 25 companies located in Oregon have contributed $180 million to Oregon’s economy. Through licensing activities and industry research collaborations, existing companies also benefit from OHSU innovations.

This tangible economic impact is part of The OHSU Effect – it’s what happens when healing, teaching and discovery come together.

Research at OHSU leads to new discoveries and brings hundreds of millions of dollars into Oregon each year, including a record high $392 million in fiscal year 2010, and a total of $358 million in fiscal year 2011. Twelve million of that came from OHSU collaborations with industry, a two million dollar increase over the prior year. Nearly 95 percent of OHSU’s total funding comes from out-of-state sources and would flow elsewhere without OHSU.

With this influx of funds, OHSU works to drive innovation and help fuel the state’s bioscience industry. Bioscience is one of Oregon’s key traded sectors, bringing much needed economic growth to our communities. The 2009 economic impact report, The Dimensions and Contributions of the Bioscience Industry in Oregon, showed that the state’s bioscience sector directly contributed $4.1 billion in revenue, at least 14,220 direct jobs, and $882 million in biotech workers’ personal income to the state economy in 2009. These numbers were up an average of 11% over the previous report, published in 2007.

The bottom line: OHSU research drives discoveries that improve healthcare, create new jobs and new businesses, and make life better for people across Oregon and beyond.